Detalhe da pesquisa
1.
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.
N Engl J Med
; 2024 Jun 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38847460
2.
NASH limits anti-tumour surveillance in immunotherapy-treated HCC.
Nature
; 592(7854): 450-456, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33762733
3.
Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver disease.
Gut
; 73(5): 825-834, 2024 Apr 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38199805
4.
Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis.
J Hepatol
; 2024 Jun 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38857788
5.
Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes.
Hepatology
; 78(1): 195-211, 2023 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36924031
6.
Impact of PNPLA3 rs738409 Polymorphism on the Development of Liver-Related Events in Patients With Nonalcoholic Fatty Liver Disease.
Clin Gastroenterol Hepatol
; 21(13): 3314-3321.e3, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37149016
7.
Validation of the Blood Test MACK-3 for the Noninvasive Diagnosis of Fibrotic Nonalcoholic Steatohepatitis: An International Study With 1924 Patients.
Clin Gastroenterol Hepatol
; 21(12): 3097-3106.e10, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37031715
8.
Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?
Gut
; 71(2): 382-390, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33541866
9.
Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis.
Gut
; 71(5): 1006-1019, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34001645
10.
Macrophage scavenger receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease.
J Hepatol
; 76(5): 1001-1012, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34942286
11.
Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease.
J Hepatol
; 75(4): 786-794, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34090928
12.
Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease.
Clin Gastroenterol Hepatol
; 19(4): 806-815.e5, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32621970
13.
Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation.
Hepatology
; 71(4): 1213-1227, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31442319
14.
Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease.
Am J Gastroenterol
; 115(8): 1289-1292, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32453041
15.
NASH in Lean Individuals.
Semin Liver Dis
; 39(1): 86-95, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30654392
16.
Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease.
J Hepatol
; 71(5): 1012-1021, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31301321
17.
Altered Metabolic Profile and Adipocyte Insulin Resistance Mark Severe Liver Fibrosis in Patients with Chronic Liver Disease.
Int J Mol Sci
; 20(24)2019 Dec 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-31888144
18.
Should we undertake surveillance for HCC in patients with NAFLD?
J Hepatol
; 68(2): 326-334, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29122695
19.
Usefulness of the index of NASH - ION for the diagnosis of steatohepatitis in patients with non-alcoholic fatty liver: An external validation study.
Liver Int
; 38(4): 715-723, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29028281
20.
Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease.
Hepatology
; 63(1): 107-16, 2016 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26473614